Sanofi S.A. (SAN) — Stock analysis
EURCurrent price
75,29 €
-1,07 € (-1.40%) today
Market signals
About Sanofi S.A.
Sanofi is one of Europe's largest pharmaceutical companies. Main therapeutic areas are immunology (Dupixent/dupilumab is its most important blockbuster drug, with indications in atopic dermatitis, asthma, COPD, eosinophilic oesophagitis), vaccines (Beyfortus, Fluzone, Dengvaxia) and rare diseases. Founded in 1973 in Paris through numerous mergers (including Aventis in 2004). Headquartered in Paris. CAC 40 component.
What does Sanofi do?▾
Sanofi is a French pharmaceutical company active in immunology (Dupixent for atopic dermatitis and asthma), vaccines (including Beyfortus for RSV in newborns and Fluzone for influenza), rare diseases and oncology. Dupixent is now its flagship drug with billions of euros in annual revenue.
Which exchange is Sanofi listed on?▾
Sanofi is listed on Euronext Paris with ticker SAN. It is a CAC 40 component. It also has ADRs on NASDAQ with ticker SNY.
Does Sanofi pay dividends?▾
Yes. It pays a growing annual dividend for over 25 consecutive years. Yield is typically 3–4%.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits